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Mucosal damage is a common side eﬀect of many cancer treatments, especially radiotherapy and intensive chemotherapy, which
often induce bone marrow (BM) suppression. We observed that acetic acid- (AA-) induced mucosal damage in the colon of
mice was worsened by simultaneous treatment with irradiation or 5-FU. However, irradiation 14 days prior to the AA treatment
augmented the recovery from mucosal damage, suggesting that the recovery from BM suppression had an advantageous eﬀect on
the mucosal repair. In addition, BM transplantation also augmented the recovery from AA-induced mucosal damage. We further
conﬁrmed that transplanted BM-derived cells, particularly F4/80+Gr1+ “inﬂammatory” monocytes (Subset 1), accumulated in
the damaged mucosal area in the early healing phase, and both of Subset 1 and F4/80+Gr1− “resident” monocytes (Subset 2)
accumulated in this area in later phases. Our results suggest that monocytes/macrophages contribute to the mucosal recovery and
regeneration following mucosal damage by anticancer drug therapy.
1.Introduction
Mucosal damage is a common side eﬀect of many cancer
treatments,especiallyintensivechemotherapyandradiother-
apy. This mucosal damage can seriously aﬀect the quality
of life of patients seriously and may sometimes demand
changes in or limit the therapy [1–3]. Intestinal mucositis
and oral mucositis are signiﬁcant clinical problems in
patientsreceivingionizingradiationastheintestinalandoral
mucosae are the most radiosensitive organs. Chemotherapy-
induced intestinal mucositis involves multiple mechanisms,
including induction of crypt cell apoptosis and cytostasis,
which implies the possible involvement of pathways relating
to p53, the Bcl-2 family, and caspases [3–5]. Further, the
n u c l e a rf a c t o r - k a p p aB[ 6], the cyclooxygenase pathway
[7], and epigenetic aberrations [8] have been implicated in
the regulation of radiation-induced mucositis. Thus, these
ﬁndings have lead to further research into the protection
and rescue of the intestinal mucosal damages in using the
experimental animals. Namely, lysophosphatidic acid [9],
Ginkgo biloba extract [10], and D-methionine [11]h a v e
been shown to exhibit protective action against radiation-
induced organ damage in vitro and in vivo. Recently, histone
deacetylase inhibitor [8], lovastatin [12], and ascorbic acid
[13] have also been shown to protect against radiation-
induced mucositis. Proinﬂammatory cytokines have also
been implicated in the pathophysiology of chemotherapy-
induced gastrointestinal mucositis [14]. However, whether
these cytokines play a key role in the development and
healing of radiotherapy-induced gastrointestinal mucositis
remains unknown.
In the present study, we employed an acetic acid- (AA-)
induced mucosal damage animal model, an established
model for the screening of the anti-inﬂammatory drugs
[15, 16], to examine the eﬀects of irradiation or 5-FU on
the healing process following AA-induced mucosal damage.2 Mediators of Inﬂammation
Surprisingly, we found that irradiation prior to AA-induced
mucosal damage enhanced mucosal healing, while the
simultaneous irradiation or 5-FU treatment simultaneously
with AA treatment exacerbated the mucosal damage. Since
irradiation or anticancer drugs therapy also induces severe
leukocytopenia, the eﬀect of bone marrow transplantation
(BMT)onmucosalhealingwasalsostudied.Inparticular,we
studied the two monocyte/macrophage subsets, “inﬂamma-
tory” and “resident” [17–21], to determine how these mono-
cyte/macrophage subsets migrate to the mucosal damaged
lesion and to elucidate their roles in mucosal healing.
Severalreportshaveshownthatmonocytes/macrophages
contribute to the healing of wounds arising from vascu-
lar injury [22], spinal cord injury [23], and myocardial
infarction [24]. Still other studies have indicated that
monocytes/macrophages may promote wound healing fol-
lowing skin injury [25–28]. However, the role of mono-
cyte/macrophage subsets in the gastrointestinal mucositis
h a sn o tb e e ne l u c i d a t e d .H e r e ,w ep r o p o s ear o l eo fm o n o -
cytes/macrophages in the protection against the intestinal
mucosal damage.
2.MaterialsandMethods
2.1. Mice and Total Body Irradiation (TBI). C57BL/6J male
mice, aged 6 weeks, were purchased from Charles River
Japan, Inc. (Yokohama). The mice were maintained under
speciﬁc pathogen-free conditions and provided with sterile
food and water ad libitum. The animals were handled and
treated in accordance with the guidelines set forth by the
animal use and care committee of the Japanese Foundation
for Cancer Research, and all procedures conformed to the
NIH guide for the Care and Use of Laboratory Animals.T h e
mice were irradiated totally with a total dose of 4Gy per
animal using an X-ray generator as a radiation therapy and
designated as RT mice. The irradiated mice were bred in a
ﬁlter-topped cage to prevent infection. The absolute count of
white blood cells (WBCs) was analyzed using an F-820 semi-
automated hematology analyzer (Sysmex, Kobe, Japan).
2.2. Induction of Experimental Mucosal Damage. Twenty
microliters of 3% AA (Wako, Tokyo, Japan) was injected into
the lumen of the colon and retained for 20s using round-
endedtweezers.Thereafter,thelumenwaswashedwithsaline
and stitched closed as described previously [9, 15, 16]. Prior
to or after mucosal damage, mice were administered 5-FU
(100mg/kg) (AA + 5-FU) i.v. via tail vein or radiation (4Gy)
(AA + Radiation Therapy (RT)) as indicated. On the day of
evaluation, the colon was longitudinally incised and spread
open, and the size of the damaged area (length × width
(mm2)) was determined using a stereoscopic microscope.
2.3. BMT and Cell Labeling. BMCs were ﬂushed from the
femur and tibia with RPMI 1640 medium using a 26G
1/2 needle. To remove debris, the suspension was ﬁltered
through a 35μm cell strainer (Falcon). The cells were then
washed with medium and counted, and 1 × 107 cells were
injected into the tail vein of each of the mucosally damaged
mice. To enable tracking analysis, BMCs were stained with
VivoTag 750 (VT750; Ex: 750 ±5nm, Em: 775 ±5nm,MW :
980Da) to visualize the accumulation of cells in vivo. VT750
was commercially obtained from VisEn Medical (Woburn,
MA; now PerkinElmer Heath Sciences, Inc.). Cells were
incubated with 30μg/ml VT750 for 30min at 37◦Ca n d
washed twice after labeling. For further analysis, BMCs were
stained with 10μM CFDA-SE (Carboxyﬂuorescein diacetate,
succinimidyl ester; Molecular probes; Invitrogen) for 15min
at 37◦C. The cells were then repelleted by centrifugation,
resuspendedinfresh,prewarmedmedium,andincubatedfor
3 0m i na tr o o mt e m p e r a t u r et oe n s u r ec o m p l e t ei n c o r p o r a -
tion of the probe before a ﬁnal washing step.
2.4. Preparation of Damaged Mucosa and Identiﬁcation of
Injected BMCs. Dissected mucosa was incubated in calcium
and magnesium-free HBSS (GIBCO) containing 2.5% heat-
inactivated FBS and 1mM DTT (Sigma-Aldrich) to remove
mucus. The mucosa was then incubated in HBSS containing
1mM EDTA (GIBCO) for 45min at 37◦C. Tissues were
then collected and incubated in HBSS containing 1mg/ml
collagenase (Nacalai Tesque, Tokyo, Japan) and 0.1mg/ml
DNase I for 60min at 37◦C, and cells were washed and
reacted with an antibody for ﬂow cytometric analysis.
2.5. Flow Cytometric Analysis. The following monoclonal
antibodies and staining reagents were used in combination
according to the manufacturers’ protocols: Phycoerythrin-
(PE-) conjugated CD11b (BD Pharmingen), Gr1 (Ly6C/G;
BDPharmingen),PeridininChlorophyllProtein-Cyanin5.5-
(PerCP-Cy5.5-) conjugated anti-CD11b (BD Pharmingen),
andallophycocyanin-(APC-)conjugatedanti-CD62L(Beck-
man Coulter), anti-Gr1 (Ly6C/G) (BD Pharmingen), or
anti-F4/80 (Caltag). To exclude nonviable cells, 7-amino-
actinomycin D (7-AAD) was used. Cells were stored in cold
conditions and protected from light; they were analyzed
approximately 15min after addition of 7-AAD. Thereafter,
c e l l sw e r ea n a l y z e do na nF A C S C a l i b u rﬂ o wc y t o m e t e r
(Becton Dickinson, Franklin Lakes, NJ) using CellQuest
software (Becton Dickinson).
2.6. Confocal Microscopic Analysis. In vivo monitoring of cell
migration was performed using the AA + 5-FU model. On
day 0, the mice were treated with AA and 5-FU (100mg/kg),
and after 24h, 1 × 107 VT750-labeled BMCs were injected
into the mice via the tail vein. On day 2, the colon was
excised from the mice, and the damaged area of the mucosa
was longitudinally incised and spread out for laser scanning
microscopy (Olympus IV100).
2.7. Statistical Analysis. Data are expressed as mean ± SE.
Data were analyzed using Welch’s t-test to compare between
two groups, Tukey’s method was used between three groups,
and diﬀerences with P<. 05 were considered statistically
signiﬁcant.
3. Results
3.1. TBI-Induced Leukocytopenia and Thrombocytopenia. It
is well known that TBI induces mucosal injury to cancerMediators of Inﬂammation 3
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Figure 1: Total body irradiation (TBI) as a radiation therapy (RT) induced leukocytopenia and thrombocytopenia. Twenty-ﬁve mice were
divided into 5 groups, and each group was irradiated by a dose of 4Gy on day 0. Mice were sacriﬁced, and white blood cells (WBC) were
counted using a semiautomated hematology analyzer F-820 (Sysmex) on day 1, 5, 10, 14, and 20, respectively (n = 5/each time point). (a)
WBC number decreased after TBI, and the low value continued around day 5. (b) Platelets number also decreased, and the lowest number
was observed around day 10. Values represent mean ± SEM. ∗P<. 05 versus day 0. Data were analyzed using the Tukey method.
patients. In order to mimic similar condition, we chose TBI
as a radiotherapy (RT) but not local irradiation. A dose of
4Gy TBI induced leukocytopenia and thrombocytopenia in
mice (Figures 1(a), 1(b)). TBI drastically reduced the WBC
count within 1 day; the WBC nadir continued for 1 week
and then gradually tended to recover. Similarly, the platelet
count decreased; however, the decrease was less severe, with
the nadir occurring on day 10. We therefore assumed that
day 14 after TBI represented a favorable stage in the recovery
phase for both WBCs and platelets.
3.2. The Relationship between Mucosal Damage and Irra-
diation. Experimental mucosal damage in the colon was
induced by 3% AA. To evaluate mucosal damage, the colon
was removed, longitudinally incised, and spread out. The
area of the damaged zone was then measured using a
stereoscopic microscope (Figure 2(a)). Concomitantly, we
examined the eﬀect of RT on mucosal damage in the colon.
When the AA-treated mice were irradiated on day 0, the
area of damage tended to be more widespread than that in
nonirradiated mice on day 7. This indicated that RT delayed
the healing of mucosal damage. Although the BMC count
did not decrease, the WBC count decreased signiﬁcantly
(Figure 2(b)). In contrast, when mice were irradiated 14
days prior to inducing mucosal damage with AA at day 0
(Pre-RT), we found that the damaged area was signiﬁcantly
decreased on day 7 (AA versus AA + Pre-RT; Figure 2(c)).
This observation suggests that preirradiation favored the
healing of mucosal damage. During these periods, the
WBC count remained lower in the irradiated mice than
in the nonirradiated mice; however, the count suggested
recovery, so we chose day 14 as Pre-RT. In addition, some
of the monocyte-derived cytokines and chemokines were
upregulated during these periods (data not shown).
3.3. Irradiation Aﬀected the Proportional Change of Monocyte
Subsets. Since Pre-RT favored the healing of mucosal dam-
age in the colon, we assumed that TBI aﬀected not only the
WBC count but also the peripheral blood monocyte subsets.
As shown in Figure 3, kinetic changes in peripheral blood
monocytesubsetswereinducedbyRT.Onemonocytesubset,
CD11b+CD62L+ Subset 1, was dominant on day 0 compared
with the CD11b+CD62L− Subset 2 (76.4% versus 23.6%).
After RT, however, the proportion gradually changed, and
the CD11b+CD62L− Subset 2 was dominant on day 10
(48.9% versus 51.1%) to day 14 (46.1% versus 53.9%), and
on day 20 the proportion returned to that observed in the
preirradiation state (72.5% versus 27.5%).
In summary, the monocyte subsets changed from Subset
1 dominance to a transient increase in Subset 2 and ﬁnally
returned to Subset 1 dominance. We speculate that Pre-RT
favored the healing of mucosal damage shown in Figure 2(c),
which may be associated with the monocyte subset changes
reported herein.
3.4. 5-FU Treatment Delayed the Healing of Mucosal Dam-
age. We next examined whether the administration of an
anticancer drug would induce the same phenomenon as4 Mediators of Inﬂammation
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Figure 2: Eﬀect of pre- or simultaneous irradiation on the acetic acid (AA-) induced mucosal damage. (a) Mucosal damage in the colon
induced by 3% AA. On the evaluated day, colon was longitudinally incised and spread. Damaged area was evaluated with stereoscopic
microscope. (b) Mice were induced mucosal damage on day 0 (AA) and irradiated on the same day (AA + RT). WBC and bone marrow cells
(BMC) on day 7 were indicated in the right panels. (c) Mice were AA treated (AA) or irradiated 14 days before AA treatment (AA + Pre-RT).
Note that the damaged area (AA + Pre-RT) was smaller than nonirradiated control (AA), indicating that preirradiation enhanced healing of
mucosal damage. WBC and BMC on day 7 were indicated in the right panels. Values represent mean ± SEM. ∗P<. 05, ∗∗P<. 01. Data were
analyzed using Welch’s t-test.
was observed with RT. Administration of 5-FU (100mg/kg)
induced leukocytopenia and BM suppression on day 7
(Figure 4(a)). When 5-FU was administered to AA-treated
mice on day 0, the damaged area increased signiﬁcantly
compared with that in saline-administered control mice on
day 7 (Figure 4(b)); that is, 5-FU treatment delayed the
healing of mucosal damage, as seen with RT. Furthermore,
the delay in the healing of mucosal damage following 5-
FU treatment was more severe than that with RT. We next
determinedtheeﬀectofBMTontheexacerbationofmucosal
damage by 5-FU treatment.
3.5. Administration of BMCs Enhanced the Healing of Mucosal
Damage. Since the BMC count was decreased by 5-FU
treatment, we assumed that BMT would help heal the
mucosal damage. Mice with AA-induced mucosal damage
that were administrated 5-FU (AA + 5-FU) underwent BMT,
and we found that BMT with 1 × 107 BMCs showed a
signiﬁcantly enhanced healing of mucosal damage 6 days
after BMT (>60%; Figure 5(a)). AA + 5-FU administration
caused signiﬁcant body weight loss compared with the sham
operation (saline-treated) group, but BMT rescued the body
weightlosssigniﬁcantlyafterday3(versusAA+5-FUgroup)Mediators of Inﬂammation 5
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Figure 3: Flow cytometric analysis of peripheral blood monocyte subsets. Five mice were sacriﬁced at each time point after RT, and whole
peripheral blood was pooled. Peripheral blood mononuclear cells (PBMC) were isolated from whole blood using gradient centrifugation
method. 1 × 106 PBMC were stained using two antibodies, CD11b-PerCP-Cy5.5 and CD62L-APC. CD11b+CD62L+ population was
designated as Subset 1, and CD11b+CD62L− population was Subset 2.
(Figure 5(b)). Heavy bleeding in the stool was observed after
the operation, particularly in the AA + 5-FU group.
3.6. Labeled BMCs Migrated into the Damaged Area of the
Mucosa. We hypothesized that transplanted BMCs migrate
into the damaged area of the mucosa and enhance its
healing. To test this hypothesis, we injected Vivotag750-
labeled BMCs into AA + 5-FU mice and determined whether
the labeled cells could be detected in the damaged area
using ﬂuorescence microscopy. As shown in Figure 6, labeled
BMCs (1×107) were markedly accumulated in the damaged
area compared with those in the undamaged areas of the
mucosa. Thus, it is possible that the labeled BMCs were
involved in the healing of the damaged mucosa.
3.7. F4/80+Gr1+ (Subset 1) Cells Accumulated in the Damaged
Area of the Mucosa in the Early Phase of Healing. To further
determine the characteristics of the accumulated cells, we
used a CFDA-SE labeling method for ﬂow cytometric
analysis (FACS). Single cells accumulated in the damaged
tissues were isolated and analyzed by FACS. The isolated cells
wereidentiﬁedbasedon1of3colors.Theywerestainedwith
7-AAD, F4/80-APC, and C11b-PE or 7-AAD, F4/80-APC,
and Gr1-PE. The CFDA-positive fraction originated from
the transplanted BMC (Figure 7(a)), which clearly expressed
CD11b and F4/80 (Figure 7(b)). However, it should be noted
that the F4/80+ fraction also expressed Gr1 (Figure 7(c)).
Thus, these analyses identiﬁed the accumulated cells in
the damaged area as F4/80+Gr1+ (Subset 1) monocytes,
which exhibited typical monocyte/macrophage morphology
(Figure 7(d)).
3.8. Both F4/80+Gr1+ (Subset 1) and F4/80+Gr1− (Subset
2) Cells Accumulated in the Damaged Area of the Mucosa
in the Later Phase of Healing. Labeled BMCs (1 × 107
cells) transplanted into AA + 5-FU mice were monitored
for 24, 72, and 120h by FACS. F4/80+Gr1+ (Subset 1)
monocytes accumulated in the damaged area of the mucosa
24h after BMT. However, Gr1 expression was weakened
72h after BMT (86.7%) and was further weakened at 120h
after BMT (51.3%) compared with the expression at 24h
(98.8%), (Figure 8). We therefore assumed that F4/80+Gr1+
(Subset 1) monocytes migrated to the damaged area of the
mucosa predominantly in the early stages of healing, while
F4/80+Gr1− (Subset 2) monocytes accumulated in the area
during the later phase.6 Mediators of Inﬂammation
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Figure 4: Eﬀect of 5-FU treatment on the AA-induced mucosal damage. (a) 5-FU induced leukocytopenia and bone marrow suppression
on day 7. Values represent mean ± SEM. Data were analyzed using the Welch’s t-test. ∗∗P<. 01, Saline versus 5-FU. (b) Mucosal damage was
induced by AA treatment on day 0 and injected 5-FU (100mg/kg) on the same day. 5-FU treatment exacerbated the mucosal damage and
delayed mucosal healing on day 7 like the simultaneous irradiation in Figure 2(b). Values represent mean ± SEM. Data were analyzed using
the Tukey method. ∗P<. 05, AA versus AA + 5-FU.
4. Discussion
Since RT or anticancer drug administration induces not only
leukocytopenia but also BM suppression, we hypothesized
that these treatments might delay the healing from mucosal
damage. We surprisingly found that preirradiation accel-
erated the healing of mucosal damage in mice that were
irradiated before the colon was damaged by AA treatment.
We also found that BMT signiﬁcantly enhanced the healing
of mucosal damage induced by AA + 5-FU treatment.
These observations strongly suggested that BMCs or a BMC-
derived cell population contributed to mucosal regeneration
following damage. We thus determined the cell type accu-
mulated in the mucosal lesion and investigated which mono-
cytes or monocyte subset played a critical role in the healing
of mucosal damage caused by irradiation or chemotherapy.
As mentioned before, mucosal damage is a common side
eﬀect of many cancer treatments, and unfortunately there
is no therapy for this disorder as yet [1–3]. Intestinal and
oral mucositis are signiﬁcant clinical problems in patients
receiving irradiation as the intestinal and oral mucosae are
the most radiosensitive organs. It was diﬃcult to establish
the mucosal injury model using irradiation or anticancer
drug alone. So, we combined AA with TBI or with 5-FUMediators of Inﬂammation 7
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Figure 5: Administration of bone marrow cells (BMC) enhanced healing mucosal damage. (a) Mucosal damage was induced by the AA
treatment and the additional administration of 5-FU (100mg/kg) on day 0 (AA + 5-FU). 1 × 107 BMC were injected into AA + 5-FU mice
on day 1. In the Sham-operated group (control), saline was injected into colon instead of AA. Administration of BMC enhanced healing
mucosal damage in AA + 5-FU mice on day 7 signiﬁcantly. (b) Comparison of changes in body weight between each group. Although AA +
5-FU mice signiﬁcantly reduce their body weight, BMT rescued the body weight loss from day 3. Values represent mean ± SEM. Data were
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Figure6:TransplantedBMCmigratedintomucosaldamagedarea.1×107 BMCwerelabeledusingVivotag750.Thesecellsweretransplanted
into AA + 5-FU model via tail vein. After 24 hours, mice were sacriﬁced, and the colon was observed. The labeled cells could be detected in
mucosal damaged area by ﬂuorescence microscope. Transplanted BMC accumulated signiﬁcantly in mucosal damaged area (b), but not in
normal area (a). Three pictures were z-axis high, middle, and low in one of the particular area.
to mimic mucosal injury in the cancer patients. We also
tried DSS (Dextran sodium sulfate) model, but it was more
complicatedbecauseDSShastheanticoagulateeﬀectbyitself
and far from the clinical context of cancer patient. Although
the AA-induced mucosal injury model is an old type, it has
widely been used for evaluating drug eﬃcacy.
The mechanism of radiation- or chemotherapy-induced
mucositis has been extensively documented [5–7] and has
enabled testing of various treatment modalities in experi-
mental animals [8–13]. Repair of tissue damage is an inter-
active process that involves soluble mediators, extracellular
matrixcomponents,residentcells,andinﬁltratingleukocytes
[28, 29]. Initially, neutrophils accumulate at wound sites,
which is followed by a large inﬂux of macrophages and a
small number of T lymphocytes. In the proliferative phase,
massive angiogenesis occurs, and ﬁbroblasts migrate into8 Mediators of Inﬂammation
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Figure 7: F4/80+CD11b+Gr1+ (Subset 1) cells accumulated at the mucosal damaged area in early phase of healing. 1×107 BMC were labeled
using CFDA-SE. These cells were injected into AA + 5-FU mice via tail vein. After 24 hours, colon was dissected and incubated in calcium
and magnesium-free HBSS containing 2.5% heat-inactivated FBS and 1mM DTT to remove mucus. After the tissues were treated with
collagenase and DNase I for 60min at 37◦C, cells were washed and stained with 7-AAD, F4/80-APC, and C11b-PE or 7-AAD, F4/80-APC,
andGr1-PE,fortheﬂowcytometricanalysis.7-AADwasusedforexclusionofdeadcells.(a)CFDA-SEpositivecellsindicatedbonemarrow-
derived cells. (b) CFDA-SE positive population was CD11b+F4/80+ monocytes. (c) F4/80 positive population was almost all Gr1+cells,
indicating the F4/80+Gr1+ Subset 1 monocytes. (d) The population had typical monocytes morphology.
the wound, proliferate, and transform into myoﬁbroblasts,
which play a major role in the formation of granulation tis-
sue. Recently, Ishida et al. using CXC3R1- (CXC chemokine
receptor 1-) knockout mice demonstrated that recruitment
of CXC3R1-positive monocytes/macrophages is critical for
skin wound healing [28].
Fluorescence resulting from illumination with an Argon
488nm, DPSS 561nm, or HeNe 633nm laser is diﬃcult
to detect during in vivo imaging of the large intestine
since mice on a normal diet exhibit autoﬂuorescence; it
is thus also diﬃcult to image the contents of the colon
and feces. Although the autoﬂuorescence can be reduced
with a puriﬁed diet, it does not completely disappear (data
not shown). Therefore, we used the following 2 methods
to detect the labeled transplanted cells. One was VT750
staining for ﬂuorescence microscopy, and the other was
CFDA-SE for FACS analysis. A 748nm LD (laser diode)
prevented autoﬂuorescence due to diet, and in our analysis,
cells and tissues in the colon could not be detected by
FACS. We thus demonstrated that F4/80+Gr1+ (Subset 1)
monocytes/macrophages were recruited to the damaged
area of the mucosa during the early phase of healing.
Both F4/80+Gr1+ (Subset 1) and F4/80+Gr1− (Subset 2)
monocytes/macrophages accumulated in the damaged
area in the later phase of the healing process. Ishida et
al. [28]r e p o r t e dt h a tb o t hC X 3CR1+CCR2− (Subset 1)
and CX3CR1+CCR2+ (Subset 2) monocytes/macrophages
accumulated in skin wound sites in the late phase of
healing and that these cells contributed to wound healing.
Our results indicated that F4/80+Gr1+ and F4/80+Gr1−
monocytes/macrophages are sequentially recruited to
damaged areas of the mucosa in 2 distinct phases. Subset
1 can be designated as immature monocytes/macrophages
and Subset 2 as mature monocytes/macrophages. Since
Subset 1 cells could possibly be classiﬁed as Subset 2 [18]
cells given the continuum of development, some proportion
of Subset 1 monocytes/macrophages may diﬀerentiate into
Subset 2 monocytes/macrophages in the late phase of healingMediators of Inﬂammation 9
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Figure 8: Both of F4/80+Gr1+ (Subset 1) and F4/80+Gr1− (Subset 2) cells accumulated mucosal damaged area in late phase. Accumulated
cells at the mucosal damaged area in late phase were analyzed at three time points after BMT. At 24 hours after BMT, almost all accumulating
cells were F4/80+Gr1+ Subset 1 monocytes (98.8%), and these Gr1+ Subset 1 monocytes decreased to 86.7% after 72 hours and 51.3% after
120 hours.
[18, 30, 31]. One study also demonstrated that monocytes
have properties similar to those of pluripotent stem cells
[32], so a particular population of monocytes may also
diﬀerentiate into mucosal cells.
Irradiation also induced upregulation of serum
cytokines, including that of G-CSF and M-CSF (data
not shown). G-CSF has been shown to have a clinically
beneﬁcial role in healing. Two randomized clinical studies
showed that G-CSF was eﬀective in reducing the incidence
of oral mucositis caused by chemotherapy [33, 34]a n d
also eﬀectively helped reduce the severity of mucositis [35].
However, several studies on G-CSF and oral mucositis have
also reported conﬂicting results. A randomized, controlled
study using a prophylactic GM-CSF mouthwash [36, 37]
and another randomized, controlled trial using a GM-CSF
mouthwash as treatment for oral mucositis in hematopoietic
stem cell transplantation patients showed no positive eﬀects
[38]. Although still controversial, topical administration
of GM-CSF appears to have some beneﬁcial eﬀects on oral
mucosal damage, its duration, and severity [39, 40].
Monocytes, a complex leukocyte population that
expresses a range of chemokine receptors, are generated
in BM and then released into circulation [17]. Mouse
monocytes are classiﬁed according to their expression of
CCR2, CD62L (L-selectin), Gr1, and CX3CR1 [17, 18].
To functionally distinguish two mouse monocyte subsets,
Geissman et al. [17] adoptively transferred GFP+ monocytes
from CX3CR1GFP/+mice to naive and immunologically
challenged mice and studied GFP+ monocyte cell fate and
function. They found that one monocyte subset expressed
CCR2,CD62L,Gr1,andonlymoderateamountsofCX3CR1,
while the other subset did not express CCR2 or CD62L but
expressed higher amounts of CX3CR1. The monocyte subset
expressing CCR2+, CD62L+,G r 1 +, and CX3CR1low was
designated the “inﬂammatory” subset (Subset 1). This
subset was rapidly recruited to the sites of experimentally
induced inﬂammation, but was short-lived after adoptive
transfer, and became diﬃcult to detect in the tissues of
naive recipients [17, 19–21]. On the other hand, the CCR2−,
CX3CR1high monocyte population was found to persist
longer in mice after adoptive transfer, and this population
was detected in the blood, spleen, lungs, liver, and brain of
recipients for several days after transfer. This population was
proposed to constitute “resident” monocytes (Subset 2) that
are recruited to tissues independently of inﬂammatory stim-
uli; these cells were also assumed to diﬀerentiate into other
populations. Recently, increasing evidence has demonstrated
that monocytes/macrophages may contribute to wound
healing following vascular injury [22], spinal cord injury
[23], and myocardial infarction [24]. Still other studies have10 Mediators of Inﬂammation
provided supporting evidence that monocytes/macrophages
may promote wound healing after skin injury [25–28]. The
relationship between monocyte/macrophage subsets and
gastrointestinal mucositis has remained unknown to date.
However, in the present study, we revealed a role played by
accumulating monocytes in AA-induced gastrointestinal
mucositis. In summary, using an animal model, we showed
that BM-derived cells, particularly monocytes/macrophages,
contribute to regeneration after mucosal damage.
5. Conclusion
Acetic acid- (AA-) induced mucosal damage of mouse colon
was worsened by simultaneous treatment with irradiation or
5-FU. However, irradiation 14 days prior to AA treatment
or BMT augmented recovery from the mucosal damage.
We conﬁrmed that F4/80+Gr1+ “inﬂammatory” monocytes
accumulated in the damaged area of the mucosa in the
early phase of healing. This study suggests that mono-
cytes/macrophages contribute to recovery and regeneration
following mucosal damage.
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